Why the study?
Direct evidence supporting the pathological relevance of elevated cfDNA in RA was lacking, and the molecular features of these cfDNA molecules were not well characterized.
Answers are grounded in this paper and cite their sources.
Specific hypomethylated CpG-motif rich cfDNA molecules in the synovial fluid of RA patients drive inflammation and may serve as novel therapeutic targets and biomarkers.
Elevated cell-free DNA (cfDNA) levels in the plasma and synovial fluid of rheumatoid arthritis (RA) patients are proposed to be pathologically relevant. However, direct evidence to support this perception is lacking, and molecular feature of the cfDNA molecules with assumed pathological function is not well characterized. Here we confirmed remarkably increased levels of total synovial fluid and plasma cfDNAs in a large cohort of patients with rheumatoid arthritis as compared to the counterparts in osteoarthritis, and demonstrate the potent inflammatogenic effects of RA synovial fluid cfDNA on both human monocyte cell line and primary cells related to RA. Massively parallel sequencing identified distinct molecular pattern of cfDNA in RA, characterized by enriching CpG-motif containing sequences. Importantly, these identified CpG-motif rich sequences are hypomethylated in RA patients and induce severe inflammatory responses both in vitro and in vivo. Our data demonstrate the pathological role of global and specific cfDNA molecules in RA, thereby identifying novel therapeutic target candidate and potential biomarker for RA.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: